Free Trial
NASDAQ:HLVX

HilleVax Q1 2025 Earnings Report

HilleVax logo
$2.08 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 +0.00 (+0.24%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

HilleVax's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HilleVax Earnings Headlines

HilleVax, Inc. Reports Q2 2025 Financial Results
Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
HilleVax Announces Merger Agreement with XOMA
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat